A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)

Ann Surg Oncol. 2023 Feb;30(2):683-685. doi: 10.1245/s10434-022-12762-z. Epub 2022 Nov 17.

Authors

Areeba Saif¹, Emily A Verbus¹, Amber Leila Sarvestani¹, Martha E Teke¹, Jacob Lambdin¹, Jonathan M Hernandez², David G Kirsch³

Affiliations

¹ Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. [email protected].
³ Radiation Oncology, Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA. [email protected].

No abstract available

Publication types

Randomized Controlled Trial
Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Extremities
Humans
Radiation Oncology*
Radiotherapy, Adjuvant
Sarcoma* / drug therapy
Sarcoma* / radiotherapy
Soft Tissue Neoplasms* / drug therapy
Soft Tissue Neoplasms* / radiotherapy

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized

Grants and funding

ZIA BC011759/ImNIH/Intramural NIH HHS/United States